405 related articles for article (PubMed ID: 30704580)
1. Cholesteryl Ester Transfer Protein Inhibition for Preventing Cardiovascular Events: JACC Review Topic of the Week.
Armitage J; Holmes MV; Preiss D
J Am Coll Cardiol; 2019 Feb; 73(4):477-487. PubMed ID: 30704580
[TBL] [Abstract][Full Text] [Related]
2. On- and off-target pharmacology of torcetrapib: current understanding and implications for the structure activity relationships (SAR), discovery and development of cholesteryl ester-transfer protein (CETP) inhibitors.
Johns DG; Duffy J; Fisher T; Hubbard BK; Forrest MJ
Drugs; 2012 Mar; 72(4):491-507. PubMed ID: 22356288
[TBL] [Abstract][Full Text] [Related]
3. Future of cholesteryl ester transfer protein (CETP) inhibitors: a pharmacological perspective.
Mohammadpour AH; Akhlaghi F
Clin Pharmacokinet; 2013 Aug; 52(8):615-26. PubMed ID: 23658137
[TBL] [Abstract][Full Text] [Related]
4. Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases.
Shinkai H
Vasc Health Risk Manag; 2012; 8():323-31. PubMed ID: 22661899
[TBL] [Abstract][Full Text] [Related]
5. No cardiovascular benefit with evacetrapib - is this the end of the road for the 'cetrapibs'?
Doggrell SA
Expert Opin Pharmacother; 2017 Oct; 18(14):1439-1442. PubMed ID: 28799819
[TBL] [Abstract][Full Text] [Related]
6. Cholesteryl ester transfer protein inhibitors in precision medicine.
Su X; Li G; Deng Y; Chang D
Clin Chim Acta; 2020 Nov; 510():733-740. PubMed ID: 32941836
[TBL] [Abstract][Full Text] [Related]
7. Cholesteryl ester transfer protein inhibition in cardiovascular risk management: ongoing trials will end the confusion.
Kappelle PJ; van Tol A; Wolffenbuttel BH; Dullaart RP
Cardiovasc Ther; 2011 Dec; 29(6):e89-99. PubMed ID: 20645987
[TBL] [Abstract][Full Text] [Related]
8. Present therapeutic role of cholesteryl ester transfer protein inhibitors.
Ferri N; Corsini A; Sirtori CR; Ruscica M
Pharmacol Res; 2018 Feb; 128():29-41. PubMed ID: 29287689
[TBL] [Abstract][Full Text] [Related]
9. Cholesteryl ester transfer protein: An enigmatic pharmacology - Antagonists and agonists.
Yamashita S; Ruscica M; Macchi C; Corsini A; Matsuzawa Y; Sirtori CR
Atherosclerosis; 2018 Nov; 278():286-298. PubMed ID: 30347344
[TBL] [Abstract][Full Text] [Related]
10. Cholesteryl ester transfer protein inhibitors: from high-density lipoprotein cholesterol to low-density lipoprotein cholesterol lowering agents?
Nurmohamed NS; Ditmarsch M; Kastelein JJP
Cardiovasc Res; 2022 Nov; 118(14):2919-2931. PubMed ID: 34849601
[TBL] [Abstract][Full Text] [Related]
11. Cholesteryl ester transfer protein inhibitors: challenges and perspectives.
Filippatos TD; Klouras E; Barkas F; Elisaf M
Expert Rev Cardiovasc Ther; 2016 Aug; 14(8):953-62. PubMed ID: 27171534
[TBL] [Abstract][Full Text] [Related]
12. Trials and Tribulations of CETP Inhibitors.
Tall AR; Rader DJ
Circ Res; 2018 Jan; 122(1):106-112. PubMed ID: 29018035
[TBL] [Abstract][Full Text] [Related]
13. Cholesteryl ester transfer protein inhibition to reduce cardiovascular risk: Where are we now?
Barter P; Rye KA
Trends Pharmacol Sci; 2011 Dec; 32(12):694-9. PubMed ID: 22088767
[TBL] [Abstract][Full Text] [Related]
14. Future of cholesteryl ester transfer protein inhibitors.
Rader DJ; deGoma EM
Annu Rev Med; 2014; 65():385-403. PubMed ID: 24422575
[TBL] [Abstract][Full Text] [Related]
15. Different effects of compounds decreasing cholesteryl ester transfer protein activity on lipoprotein metabolism.
Niesor EJ
Curr Opin Lipidol; 2011 Aug; 22(4):288-95. PubMed ID: 21587074
[TBL] [Abstract][Full Text] [Related]
16. The therapeutic potential of CETP inhibitors: a patent review.
Wang X; Li W; Hao L; Xie H; Hao C; Liu C; Li W; Xiong X; Zhao D
Expert Opin Ther Pat; 2018 Apr; 28(4):331-340. PubMed ID: 29424255
[TBL] [Abstract][Full Text] [Related]
17. Investigational CETP antagonists for hyperlipidemia and atherosclerosis prevention.
Sirtori CR
Expert Opin Investig Drugs; 2011 Nov; 20(11):1543-54. PubMed ID: 21961529
[TBL] [Abstract][Full Text] [Related]
18. Effects of cholesteryl ester transfer protein inhibitors on human lipoprotein metabolism: why have they failed in lowering coronary heart disease risk?
Schaefer EJ
Curr Opin Lipidol; 2013 Jun; 24(3):259-64. PubMed ID: 23652567
[TBL] [Abstract][Full Text] [Related]
19. Cholesteryl Ester Transfer Protein Inhibitors and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Taheri H; Filion KB; Windle SB; Reynier P; Eisenberg MJ
Cardiology; 2020; 145(4):236-250. PubMed ID: 32172237
[TBL] [Abstract][Full Text] [Related]
20. Association of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein Levels and Cardiovascular Risk.
Ference BA; Kastelein JJP; Ginsberg HN; Chapman MJ; Nicholls SJ; Ray KK; Packard CJ; Laufs U; Brook RD; Oliver-Williams C; Butterworth AS; Danesh J; Smith GD; Catapano AL; Sabatine MS
JAMA; 2017 Sep; 318(10):947-956. PubMed ID: 28846118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
